Decheng Capital LLC Makes New Investment in Lyell Immunopharma, Inc. (NASDAQ:LYEL)

Decheng Capital LLC acquired a new position in Lyell Immunopharma, Inc. (NASDAQ:LYEL - Free Report) in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 11,909,341 shares of the company's stock, valued at approximately $7,622,000. Lyell Immunopharma makes up approximately 1.6% of Decheng Capital LLC's investment portfolio, making the stock its 13th biggest holding. Decheng Capital LLC owned approximately 4.08% of Lyell Immunopharma at the end of the most recent quarter.

Other institutional investors have also added to or reduced their stakes in the company. Renaissance Technologies LLC lifted its position in shares of Lyell Immunopharma by 716.7% during the 4th quarter. Renaissance Technologies LLC now owns 1,612,146 shares of the company's stock valued at $1,032,000 after buying an additional 1,414,746 shares in the last quarter. Takeda Pharmaceutical Co. Ltd. bought a new position in Lyell Immunopharma during the fourth quarter valued at $527,000. Johnson & Johnson bought a new stake in shares of Lyell Immunopharma in the 4th quarter worth about $527,000. Charles Schwab Investment Management Inc. lifted its holdings in shares of Lyell Immunopharma by 43.4% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 1,645,787 shares of the company's stock worth $1,053,000 after acquiring an additional 498,417 shares during the last quarter. Finally, JPMorgan Chase & Co. lifted its holdings in Lyell Immunopharma by 347.8% during the 4th quarter. JPMorgan Chase & Co. now owns 433,265 shares of the company's stock valued at $277,000 after buying an additional 336,516 shares in the last quarter. Institutional investors own 66.05% of the company's stock.

Lyell Immunopharma Stock Down 2.6 %

Shares of LYEL traded down $0.01 during mid-day trading on Thursday, reaching $0.46. The company had a trading volume of 233,936 shares, compared to its average volume of 938,291. Lyell Immunopharma, Inc. has a 52-week low of $0.39 and a 52-week high of $2.88. The stock has a market capitalization of $136.74 million, a P/E ratio of -0.59 and a beta of -0.26. The stock has a 50 day moving average of $0.54 and a two-hundred day moving average of $0.72.

Lyell Immunopharma (NASDAQ:LYEL - Get Free Report) last released its quarterly earnings results on Wednesday, March 12th. The company reported ($0.72) earnings per share for the quarter, missing analysts' consensus estimates of ($0.20) by ($0.52). Lyell Immunopharma had a negative return on equity of 34.64% and a negative net margin of 323,792.09%. The business had revenue of $0.01 million during the quarter. On average, sell-side analysts expect that Lyell Immunopharma, Inc. will post -0.78 earnings per share for the current year.

Insider Buying and Selling

In other Lyell Immunopharma news, Director Richard Klausner purchased 158,000 shares of the firm's stock in a transaction on Friday, March 14th. The stock was bought at an average price of $0.60 per share, with a total value of $94,800.00. Following the transaction, the director now directly owns 843,365 shares of the company's stock, valued at approximately $506,019. This represents a 23.05 % increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO Charles W. Newton bought 200,000 shares of the stock in a transaction that occurred on Monday, March 17th. The shares were bought at an average cost of $0.56 per share, with a total value of $112,000.00. Following the completion of the purchase, the chief financial officer now directly owns 200,000 shares in the company, valued at $112,000. This represents a ∞ increase in their ownership of the stock. The disclosure for this purchase can be found here. In the last quarter, insiders purchased 768,640 shares of company stock valued at $449,508. Company insiders own 25.10% of the company's stock.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reissued a "neutral" rating and set a $1.00 target price on shares of Lyell Immunopharma in a research report on Wednesday, April 16th.

Lyell Immunopharma Company Profile

Lyell Immunopharma, Inc, a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic.